At what hemoglobin level should phlebotomy be initiated and what target hemoglobin range should be maintained in patients with autosomal dominant polycystic kidney disease (ADPKD)?

Phlebotomy for Erythrocytosis in ADPKD

In patients with ADPKD who develop erythrocytosis, therapeutic phlebotomy should be initiated when hemoglobin exceeds 17 g/dL (hematocrit >51%) and an ACE inhibitor or ARB is either contraindicated or ineffective at maximal-tolerated dose. 1

When to Perform Phlebotomy

The 2025 KDIGO ADPKD guideline provides the clearest directive: phlebotomy is indicated specifically for erythrocytosis (hemoglobin >17 g/dL or hematocrit >51%), not for routine anemia management 1. This is a critical distinction—ADPKD patients typically maintain higher hemoglobin levels than other CKD patients due to regional hypoxia driving erythropoietin production from cyst-compressed kidney tissue 2.

First-Line Management

• Try ACE inhibitor or ARB first at maximal-tolerated doses
• These medications can suppress erythrocytosis without phlebotomy
• Only proceed to phlebotomy if pharmacologic management fails or is contraindicated 1

Monitoring During Phlebotomy

While the ADPKD guidelines don't specify exact hemoglobin targets during phlebotomy, extrapolating from hemochromatosis guidelines (the most relevant phlebotomy protocols available):

• Check hemoglobin before each phlebotomy session 3
• Reduce phlebotomy frequency if hemoglobin drops below 12 g/dL 3
• Discontinue phlebotomy if hemoglobin falls below 11 g/dL 3

Critical Context: The Anemia Paradox in ADPKD

Do not confuse erythrocytosis management with anemia management—these are opposite problems requiring opposite approaches:

Erythrocytosis (Hemoglobin >17 g/dL)

• Occurs in some ADPKD patients, especially post-transplant 1, 4
• Managed with ACE-I/ARB first, then phlebotomy if needed
• Post-transplant: 14% required phlebotomy in first year vs 4% of controls 4

Anemia (Lower Hemoglobin)

Recent evidence shows anemia is actually a negative prognostic marker in ADPKD:

• Hemoglobin <12 g/dL associated with worse kidney outcomes in women 5
• Hemoglobin <13 g/dL associated with worse kidney outcomes in men 5
• Lower hemoglobin independently predicts kidney disease progression 6

This creates a narrow therapeutic window—you want to avoid both erythrocytosis (>17 g/dL) and significant anemia (<12-13 g/dL depending on sex).

Common Pitfalls

1. Don't perform routine phlebotomy just because a patient has ADPKD—only for documented erythrocytosis 1

2. Don't use general CKD anemia targets (9-11.5 g/dL from KDIGO CKD guidelines 7)—these don't apply to ADPKD patients who naturally maintain higher hemoglobin

3. Don't ignore sex differences: Men tolerate higher hemoglobin (up to 13 g/dL appears safe), while women show adverse outcomes below 12 g/dL 5

4. Post-transplant vigilance: Erythrocytosis occurs more frequently after kidney transplantation in ADPKD patients 1, 4—monitor closely in the first year

Practical Algorithm

For ADPKD patients with elevated hemoglobin:

1. Hemoglobin 13-17 g/dL: Monitor, no intervention needed (this is actually protective in ADPKD)

2. Hemoglobin >17 g/dL (or hematocrit >51%):

   • Start ACE inhibitor or ARB at maximal-tolerated dose
   • If contraindicated or ineffective → proceed to phlebotomy

3. During phlebotomy:

   • Remove 400-500 mL per session (standard unit)
   • Check hemoglobin before each session
   • Target: reduce to <17 g/dL but maintain >12 g/dL
   • If hemoglobin drops to 12 g/dL → reduce frequency
   • If hemoglobin drops to 11 g/dL → stop and reassess

The evidence base for phlebotomy in ADPKD is limited, requiring extrapolation from hemochromatosis protocols 3, 8 while respecting the unique physiology of ADPKD where higher hemoglobin appears beneficial until frank erythrocytosis develops.